Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
Lung cancer is the common malignant tumor with the highest mortality rate. Lung cancer patients have achieved benefits from immunotherapy, including immune checkpoint inhibitors (ICIs) therapy. Unfortunately, cancer patients acquire adaptive immune resistance, leading to poor prognosis. Tumor microe...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1132158/full |
| _version_ | 1797924630254583808 |
|---|---|
| author | Man Wang Lijie Zhu Xiaoxu Yang Jiahui Li Yu’e Liu Ying Tang |
| author_facet | Man Wang Lijie Zhu Xiaoxu Yang Jiahui Li Yu’e Liu Ying Tang |
| author_sort | Man Wang |
| collection | DOAJ |
| description | Lung cancer is the common malignant tumor with the highest mortality rate. Lung cancer patients have achieved benefits from immunotherapy, including immune checkpoint inhibitors (ICIs) therapy. Unfortunately, cancer patients acquire adaptive immune resistance, leading to poor prognosis. Tumor microenvironment (TME) has been demonstrated to play a critical role in participating in acquired adaptive immune resistance. TME is associated with molecular heterogeneity of immunotherapy efficacy in lung cancer. In this article, we discuss how immune cell types of TME are correlated with immunotherapy in lung cancer. Moreover, we describe the efficacy of immunotherapy in driven gene mutations in lung cancer, including KRAS, TP53, EGFR, ALK, ROS1, KEAP1, ZFHX3, PTCH1, PAK7, UBE3A, TNF-α, NOTCH, LRP1B, FBXW7, and STK11. We also emphasize that modulation of immune cell types of TME could be a promising strategy for improving adaptive immune resistance in lung cancer. |
| first_indexed | 2024-04-10T15:03:55Z |
| format | Article |
| id | doaj.art-289f1c6b014540d7b75aea84a7d51e4b |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-10T15:03:55Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-289f1c6b014540d7b75aea84a7d51e4b2023-02-15T06:25:49ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-02-011410.3389/fphar.2023.11321581132158Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancerMan Wang0Lijie Zhu1Xiaoxu Yang2Jiahui Li3Yu’e Liu4Ying Tang5Department of Respiratory Medicine, The First Hospital of Jilin University, Changchun, Jilin, ChinaDepartment of Respiratory Medicine, The First Hospital of Jilin University, Changchun, Jilin, ChinaDepartment of Respiratory Medicine, The First Hospital of Jilin University, Changchun, Jilin, ChinaDepartment of Respiratory Medicine, The First Hospital of Jilin University, Changchun, Jilin, ChinaTongji University Cancer Center, Shanghai Tenth People’s Hospital of Tongji University, School of Medicine, Tongji University, Shanghai, ChinaDepartment of Respiratory Medicine, The First Hospital of Jilin University, Changchun, Jilin, ChinaLung cancer is the common malignant tumor with the highest mortality rate. Lung cancer patients have achieved benefits from immunotherapy, including immune checkpoint inhibitors (ICIs) therapy. Unfortunately, cancer patients acquire adaptive immune resistance, leading to poor prognosis. Tumor microenvironment (TME) has been demonstrated to play a critical role in participating in acquired adaptive immune resistance. TME is associated with molecular heterogeneity of immunotherapy efficacy in lung cancer. In this article, we discuss how immune cell types of TME are correlated with immunotherapy in lung cancer. Moreover, we describe the efficacy of immunotherapy in driven gene mutations in lung cancer, including KRAS, TP53, EGFR, ALK, ROS1, KEAP1, ZFHX3, PTCH1, PAK7, UBE3A, TNF-α, NOTCH, LRP1B, FBXW7, and STK11. We also emphasize that modulation of immune cell types of TME could be a promising strategy for improving adaptive immune resistance in lung cancer.https://www.frontiersin.org/articles/10.3389/fphar.2023.1132158/fullTMEPD-L1PD-1timeimmunotherapyresistance |
| spellingShingle | Man Wang Lijie Zhu Xiaoxu Yang Jiahui Li Yu’e Liu Ying Tang Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer Frontiers in Pharmacology TME PD-L1 PD-1 time immunotherapy resistance |
| title | Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer |
| title_full | Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer |
| title_fullStr | Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer |
| title_full_unstemmed | Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer |
| title_short | Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer |
| title_sort | targeting immune cell types of tumor microenvironment to overcome resistance to pd 1 pd l1 blockade in lung cancer |
| topic | TME PD-L1 PD-1 time immunotherapy resistance |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1132158/full |
| work_keys_str_mv | AT manwang targetingimmunecelltypesoftumormicroenvironmenttoovercomeresistancetopd1pdl1blockadeinlungcancer AT lijiezhu targetingimmunecelltypesoftumormicroenvironmenttoovercomeresistancetopd1pdl1blockadeinlungcancer AT xiaoxuyang targetingimmunecelltypesoftumormicroenvironmenttoovercomeresistancetopd1pdl1blockadeinlungcancer AT jiahuili targetingimmunecelltypesoftumormicroenvironmenttoovercomeresistancetopd1pdl1blockadeinlungcancer AT yueliu targetingimmunecelltypesoftumormicroenvironmenttoovercomeresistancetopd1pdl1blockadeinlungcancer AT yingtang targetingimmunecelltypesoftumormicroenvironmenttoovercomeresistancetopd1pdl1blockadeinlungcancer |